Follistatin-344
FS-344 · FST344 · FST-344 · follistatin isoform FS344
Last updated
At a glance
Overview
Follistatin-344 occupies a specific, interesting niche in the physique-enhancement toolkit: it's a peptide used to coax growth in a stubborn, lagging muscle that fails to respond to training stimulus or AAS. Unlike systemic anabolics, FS-344's defining feature is its C-terminal heparin-binding tail — a structural quirk that tethers the peptide to tissue at the injection site instead of letting it wash into circulation. That makes it a site-specific tool, and site-specific is the entire reason to bother with it.
Mechanistically, it works by neutralizing myostatin, activin, and related TGF-β ligands, cutting off the brake signal on muscle growth and letting the Akt/mTOR pathway run unchecked in the targeted tissue. Primate gene-therapy work produced roughly 10–15% quadriceps hypertrophy at the injected leg without disturbing pituitary FSH or reproductive function — impressive numbers, though pinned peptide produces far more modest results than continuous AAV-driven expression.
"Rhesus macaques received AAV1-FS344 gene transfer, resulting in robust increases in muscle size—up to 15% hypertrophy—without adverse effects on pituitary FSH or reproductive function." — Kota et al., Science Translational Medicine (2009)
Experienced users run FS-344 as a layered tool, not a base — 100–200 mcg/day SC directly over a lagging muscle, 2–4 week cycles, typically stacked with IGF-1 LR3, MGF, or a GH/GHRP base for pathway-diverse hypertrophy. It's not a replacement for testosterone, it's not a recomp miracle, and megadose 1 mg protocols come with a documented central serous chorioretinopathy (CSCR) signal that you do not want to ignore. Below we cover the full dosage ladder and site-specific injection protocol, realistic cycle structure, stack architecture for physique and peptide-only blocks, the CSCR and tendon-lag risks that bound the dose ceiling, and the community practice patterns that separate a productive cycle from wasted vials.
How Follistatin-344 works
Myostatin and Activin Blockade — the Headline Mechanism#
Follistatin is a high-affinity decoy that sequesters myostatin (GDF-8), activin A/B, GDF-11, and several BMPs before they can engage the ActRIIB / ALK4-5 receptor complex. With those ligands neutralized, downstream SMAD2/3 phosphorylation collapses, which in turn shuts down the atrogene program (MuRF1, atrogin-1) and removes the brake on Akt/mTOR-driven protein synthesis. The practical readout is myofiber hypertrophy — and in some models, frank hyperplasia — in the muscles exposed to the peptide.
"Follistatin binds myostatin, activins, and related TGF-β superfamily ligands, preventing their engagement of the ActRIIB receptor complex and resulting in enhanced skeletal muscle growth." — Rodino-Klapac LR et al., Muscle & Nerve, 2009
This is the mechanism people are actually buying when they pin FS-344: a pharmacological release of the myostatin ceiling on the injected muscle.
Why the "344" Isoform Specifically — the Heparin-Binding Tail#
Three isoforms matter: FS-288 (tissue-bound, reproductive), FS-315 (the dominant circulating form), and FS-344, the full-length precursor that carries an intact C-terminal acidic / heparin-binding tail. That tail is the entire reason physique users choose it. Instead of diffusing away into circulation, FS-344 tethers itself to heparan sulfate proteoglycans on cell surfaces at the injection site, concentrating myostatin blockade in the tissue directly under the needle.
"The C-terminal domain of FS-344 — absent in FS-288 — drives local tissue anchoring by binding cell-surface heparan sulfate, restricting systemic diffusion and amplifying localized activity following site-specific administration." — Walker RG et al., Experimental Biology and Medicine, 2020
Translation: to bring up a lagging lateral delt or medial calf, FS-344 is administered SC over that muscle. Injecting FS-344 into a convenient abdominal fold and expecting whole-body growth misunderstands the molecule.
Local Pharmacokinetics and the "Short Half-Life" Paradox#
Recombinant follistatin has famously poor circulating PK. Datta-Mannan and colleagues clocked terminal serum half-life at under an hour in rodents, driven by heparan-sulfate binding and renal filtration — so poor that engineering an Fc fusion was needed to get meaningful systemic exposure.
"Recombinant follistatin-315, and by extension follistatin-344, demonstrated rapid clearance from circulation, with a terminal serum half-life in rodents of less than 1 hour, driven by heparan-sulfate binding and renal filtration." — Datta-Mannan A et al., Journal of Pharmacology and Experimental Therapeutics, 2013
For site-specific use this is a feature, not a bug. The same heparan-sulfate affinity that destroys systemic half-life creates a tissue depot at the injection site. Circulating levels are trivial within hours; local tissue activity persists meaningfully longer. This is also why the primate gene-therapy data is so much more dramatic than anything achievable with peptide injection — AAV1-FS344 produced ~15% sustained hypertrophy in rhesus macaques because the muscle itself was converted into a continuous follistatin factory.
"Rhesus macaques received AAV1-FS344 gene transfer, resulting in robust increases in muscle size — up to 15% hypertrophy — without adverse effects on pituitary FSH or reproductive function." — Kota J et al., Science Translational Medicine, 2009
Intermittent SC peptide cannot replicate that exposure profile. Expect subtle, local, muscle-specific fullness — not a myostatin-null transformation.
Satellite Cell Recruitment and Anti-Fibrotic Signalling#
Beyond raw myostatin blockade, follistatin accelerates satellite-cell activation and myoblast differentiation, feeding new myonuclei into the growing fiber pool. It also exerts an anti-fibrotic effect in skeletal muscle, limiting collagen scar deposition after injury. This is the mechanistic basis for layering FS-344 alongside IGF-1 LR3 or MGF at the same depot site — IGF-1 signalling drives satellite-cell proliferation, follistatin removes the myostatin brake on their fusion, and the two pathways stack cleanly rather than redundantly.
For users running FS-344 into rehabbing tissue, the anti-fibrotic and satellite-cell effects are arguably more valuable than the hypertrophy itself.
FSH / HPG Axis — a Real but Dose-Dependent Consideration#
Follistatin was originally named for its ability to suppress follicle-stimulating hormone by neutralizing activin at the pituitary. At realistic site-specific SC doses (100–200 mcg), systemic exposure is low enough that HPG effects are largely theoretical. At the gram-level bolus doses tied to the CSCR case series, systemic activin blockade becomes plausible and fertility becomes a real concern. Anyone actively trying to conceive should leave FS-344 out of the stack — and that's before considering the retinal signal that accompanies the same megadose protocols.
The takeaway: FS-344's mechanism is elegant but exposure-bounded. Keep the dose local and the cycle short, and the molecule does what it's supposed to do. Push it into systemic territory chasing primate gene-therapy numbers and you trade the safety profile for effects the peptide route can't deliver anyway.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 50–100 mcg | Once daily | Documented entry-level range |
| Mid | 100–200 mcg | Once daily | Most commonly studied range |
| High | 300–500 mcg | Once daily | Inject SubQ directly over the target muscle — the C-terminal heparin-binding tail tethers it to local tissue, so site selection is the entire point. Advanced users split AM/PM. Avoid single-bolus gram-level dosing (CSCR signal). |
Cycle length & outcomes
Documented cycle
2–4 weeks
Plateau after
4 wks
Cycle Length & Onset#
Follistatin-344 is run in short, site-specific blocks, not long open-ended courses. The peptide's value lives in localized myostatin blockade at the depot site — the C-terminal heparin-binding tail keeps it tethered to tissue near the injection rather than flooding circulation — so cycle design is about saturating one muscle for a few weeks and then getting out.
"The C-terminal domain of FS-344—absent in FS-288—drives local tissue anchoring by binding cell-surface heparan sulfate, restricting systemic diffusion and amplifying localized activity following site-specific administration." — Walker et al., Experimental Biology and Medicine (2020)
Most credible logs run 15–30 days. Two rationales drive the cap: (1) the measurable local fullness and myofiber response show up inside the first two weeks and plateau, and (2) theoretical tendon-lag and fibrosis concerns scale with exposure time. Running FS-344 year-round is pointless and unwise — bank the localized stimulus, cycle off, let connective tissue catch up, repeat next block if needed.
Dose Ladder by Goal#
| Goal | Cycle Length | Daily Dose | Notes |
|---|---|---|---|
| First run / tolerance check | 10–14 days | 50–100mcg SC | Single site, AM injection |
| Lagging muscle bring-up | 20–30 days | 100–200mcg SC | Site-specific over target muscle, bilateral if symmetrical |
| Aggressive recomp block | 30 days | 300–500mcg SC | Split AM/PM across two sites, not one bolus |
| Peptide stack layer (with GH + IGF-1 LR3) | 20–30 days | 100mcg SC | Same depot as IGF-1 LR3 pre-workout |
Do not run 1mg single-bolus protocols. That's the dose profile that produced the CSCR case series:
"Eleven male bodybuilders developed central serous chorioretinopathy after self-injecting 1 mg follistatin-344 subcutaneously; vision changes resolved gradually after cessation, highlighting a risk with high-dose use." — Dağ et al., International Ophthalmology (2020)
To achieve higher daily exposure, split AM/PM across two smaller injections at different muscles rather than stacking one gram into the abdomen.
Onset Timing#
- Local fullness / pump response: days 3–7 in the injected muscle
- Measurable hypertrophy at the depot site: weeks 2–4
- Peak circulating exposure: minutes after SC injection (trivial systemically by design)
"Recombinant follistatin-315, and by extension follistatin-344, demonstrated rapid clearance from circulation, with a terminal serum half-life in rodents of less than 1 hour, driven by heparan-sulfate binding and renal filtration." — Datta-Mannan et al., JPET (2013)
The ~1-hour circulating half-life is why daily dosing is the floor and why site selection matters more than timing. Injecting FS-344 into abdominal fat and expecting systemic physique effects is a misuse of the molecule — that's not how this isoform works. Inject SC directly into the subcutaneous tissue over the target muscle (lateral delt, long-head bicep, medial calf, etc.) and let the heparin-binding tail do its job.
Tapering, Loading & Stacking Cadence#
No loading phase required. Full daily dose from day one. Ramping makes sense only as a tolerance check on a first run (50mcg × 3 days → 100mcg).
No taper required. Cold-stop at the end of the block. FS-344 does not suppress the HPTA and does not require PCT on the androgen axis. Activin-mediated FSH suppression is a theoretical concern only at systemic megadoses; at 100–200mcg/day site-specific SC, it's not driving anything pituitary.
Stacking cadence:
- IGF-1 LR3 (20–40mcg pre-workout) into the same depot site — different pathway (IGF-1R direct), stacks cleanly
- MGF post-workout at the same site — satellite-cell recruitment layer
- HGH 2–4 IU/day or CJC-1295 + ipamorelin — systemic GH/IGF-1 axis, orthogonal to myostatin blockade
- TRT or moderate blast as the hormonal base — FS-344 is a layer, not a standalone anabolic
Bloodwork & Monitoring Cadence#
FS-344 doesn't move hormones the way AAS do, so the monitoring burden is light — but there is one compound-specific check: eyes.
| Panel | When |
|---|---|
| Baseline CBC, CMP, lipids, hormone panel | Before first cycle |
| Standard on-cycle panel | Mid-cycle if stacked with AAS/GH |
| Dilated retinal exam / OCT | Annually for anyone running repeated or higher-dose cycles |
| Immediate ophthalmology referral | Any central vision blur, metamorphopsia, or dark central spot on or after cycle |
The CSCR signal is dose-dependent and appears tied to gram-level bolus exposure, not physiologic site-specific dosing — but anyone with a history of central serous retinopathy, steroid-induced retinopathy, or active retinopathy should skip follistatin entirely. No cycle is worth a chorioretinal complication.
Men actively trying to conceive should also hold off during the cycle window given follistatin's original role as an FSH-suppressing factor, even if real-world suppression at these doses is likely minimal.
Realistic Expectations#
Kota's primate data showed ~15% local hypertrophy — but that was continuous AAV-driven gene expression, not intermittent peptide injection:
"Rhesus macaques received AAV1-FS344 gene transfer, resulting in robust increases in muscle size—up to 15% hypertrophy—without adverse effects on pituitary FSH or reproductive function." — Kota et al., Science Translational Medicine (2009)
Injectable recombinant FS-344 at community doses produces a fraction of that — subtle local fullness, modest measurable growth in the injected muscle, and a useful layer on top of a dialed training and hormonal base. Run it short, run it site-specific, stack it intelligently, and respect the CSCR ceiling. Used that way, it earns its slot as a targeted bring-up tool for the one muscle that refuses to grow on everything else.
Body Transformation Preview
Lean Mass Gain
0.5 lbs
0.4–0.6 lbs range
Fat Loss
0.0 lbs
0.0–0.0 lbs range
Lean Gain by Week
Risks & mistakes
Common (most users)#
- Injection-site reactions — mild redness, transient sting, or pinpoint bruising over the target muscle. Rotate within the same muscle belly, use a fresh 29–31G insulin pin per injection, and keep the solution cold. If a site stays lumpy or tender, move 2–3cm over.
- Transient fatigue or mild headache — occasionally reported in the first few days of a run. Usually self-resolving within a week; if it persists, drop to the low end of the ladder (50–100mcg) before cycling back up.
- Local muscle fullness / tightness at the injection site — expected, not a side effect per se. Stretch and massage the area; do not train that muscle to hard failure the day of a pin while you're still calibrating load tolerance.
Uncommon (dose-dependent or individual)#
- Tendon / connective-tissue lag — myostatin-null animal models show disproportionately brittle tendons relative to hypertrophied muscle bellies. Aggressive, sustained blockade plausibly outruns tendon adaptation. Keep loading progressive, not reckless, and back off volume if you feel new nagging insertional pain (elbow, patellar, Achilles).
- FSH suppression (theoretical at community doses) — follistatin was literally named for its activin-mediated suppression of FSH. At 100–200mcg SC site-specific, systemic exposure is trivial and this is unlikely to matter. At gram-level bolus dosing it becomes real. Individuals running aggressive protocols who plan to conceive should obtain an LH/FSH/total T panel before and after.
"Recombinant follistatin-315, and by extension follistatin-344, demonstrated rapid clearance from circulation, with a terminal serum half-life in rodents of less than 1 hour, driven by heparan-sulfate binding and renal filtration." — Datta-Mannan et al., JPET (2013)
- Fibrosis / hyperplasia concerns — flagged in review literature, not documented at community peptide doses. Keeping cycles short (2–4 weeks) rather than continuous is the conservative answer.
- Peptide hypersensitivity — rare with a well-sourced product. Itching, hives, or flushing beyond the local site means stop and don't re-challenge.
Rare but serious#
- Central serous chorioretinopathy (CSCR) — the one documented high-severity signal. Eleven male bodybuilders developed subretinal fluid and decreased visual acuity after 1mg SC abdominal bolus injections of follistatin-344. Single-dose cases resolved over ~2.3 months; repeated high-dose exposure produced recurrent disease.
"Eleven male bodybuilders developed central serous chorioretinopathy after self-injecting 1 mg follistatin-344 subcutaneously; vision changes resolved gradually after cessation, highlighting a risk with high-dose use." — Dağ et al., International Ophthalmology (2020)
Warning signs: central vision blurring, a dark or distorted spot in central vision (metamorphopsia), colors looking washed out, or straight lines appearing bent. Stop immediately and see an ophthalmologist. An OCT scan confirms it.
- Vision changes of any kind during or after a cycle — treat as CSCR until an eye exam says otherwise. Do not "push through" visual symptoms on a follistatin run.
Hard contraindications#
- History of central serous chorioretinopathy, steroid-induced retinopathy, or active retinopathy — do not run follistatin-344 at any dose.
- Single-bolus gram-level dosing (1mg+ SC) — this is the exact protocol that produced the CSCR case series. Do not do it. Stay in the 50–500mcg/day range, split if going high.
- Active conception attempt — theoretical FSH suppression plus a thin safety database in reproductive-age users makes this the wrong cycle to run if you're trying to get a partner pregnant in the next 3–6 months.
- Active malignancy — a broad growth-signaling peptide that blocks a major tumor-suppressor pathway (TGF-β) has no business being run alongside active cancer. Full stop.
- Peptide hypersensitivity — prior anaphylactoid reaction to any recombinant peptide is a no-go.
Gender, PCT, and monitoring#
Follistatin-344 is non-hormonal and non-androgenic — no virilization risk in women and no PCT required on the HPTA axis. That said, the clinical safety database in women is effectively nonexistent; same site-specific SC dosing applies, and the CSCR contraindication is gender-agnostic.
For individuals running aggressive protocols (300mcg+/day, or repeat cycles), add an annual dilated retinal exam or OCT to standard on-cycle bloodwork (CBC, CMP, lipids, hormone panel). That single monitoring add-on covers the one serious signal in the literature and keeps the rest of the profile as clean as the mechanism suggests it should be.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| additive | ×1.08 | ×1.00 | ×1.05 |
FAQ — Follistatin-344
Where to buy
Swiss Chems
Affiliate link — we may earn a commission at no cost to you.
- Buy Follistatin-344 1 mg (1 vial) - SwissChems - Buy Best Quality Peptides, SARMS OnlineBuy Follistatin-344
Research & citations
5 studies cited on this page.
Conclusion
Follistatin-344 delivers a unique, site-specific hypertrophy signal — not a systemic bulk agent, but a focused tool for bringing up stubborn muscles when everything else is dialed in.
Key takeaways:
- Standard dose: 100–200 µg per day, subcutaneously over the target muscle
- Cycle duration: 2–4 weeks; longer cycles give diminishing returns and more risk
- Route matters — inject directly over the muscle you want to improve, not systemically
- Never megadose: avoid 1 mg+ single shots (risk of central serous chorioretinopathy)
- Best results come when stacked with IGF-1 LR3 or MGF for local synergy, and layered onto a solid training protocol
- Safe for women; no androgenic or HPTA suppression, but fertility and retinal safety data are limited
If you want subtle, reproducible local muscle gain as the last 5–10% edge, FS-344 is the real deal when used smartly — just respect dosing and pin it with precision.